Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company dedicated to developing and commercializing therapies for the treatment of various eye disorders. The company primarily focuses on retinal and refractive eye disorders, targeting conditions such as diabetic retinopathy and diabetic macular edema. Ocuphire's lead product candidate, APX3330, is an oral tablet taken twice daily, designed to inhibit angiogenesis (the formation of new blood vessels) and inflammatory pathways relevant to retinal and choroidal vascular diseases. The company operates in the biopharmaceutical market, serving patients with eye disorders and collaborating with healthcare providers and research institutions to bring its therapies to market. Ocuphire's business model revolves around the clinical development and eventual commercialization of its drug candidates. Revenue generation is expected to come from the successful approval and sale of its therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical companies. The company aims to address unmet medical needs in ophthalmology, providing innovative solutions to improve patients' vision and quality of life.

Keywords: ophthalmic, biopharmaceutical, retinal disorders, refractive disorders, diabetic retinopathy, macular edema, angiogenesis inhibition, inflammation pathways, clinical-stage, eye therapies.